Brief introduction of Shandong International Biotechnology Park

Shandong International Bio-Science Park was jointly built by Yantai High-tech Zone Management Committee and Lvye Investment Group Co., Ltd. with the strong support of Shandong Science and Technology Department and Yantai Municipal Government. It is a new attempt to construct an innovation system to explore and adopt the domestic operation mode of "government-enterprise cooperation", advocate the new concept of healthy scientific and technological life, create the best research and development environment and the best living environment according to international standards, and provide all-round services from technology to capital to life for entrepreneurial enterprises and institutions entering the park. Functionally, the park mainly focuses on research and development, and mainly focuses on biomedicine, marine life, bio-agriculture and medical care.

During the Eleventh Five-Year Plan period, Shandong International Biotechnology Park has been listed as an important part of the national comprehensive new drug research and development technology platform "Shandong Major New Drug Creation Center" and has become the national innovative drug (Yantai) incubation base.

The park is located at a high point, based on the development of emerging industries, and vigorously promotes the construction of modern biomedical industry innovation system. It has successively cooperated with Yantai Branch of Shanghai Institute of Pharmacology of China Academy of Sciences, Tongji University, Shanghai University of Traditional Chinese Medicine, China Pharmaceutical University, Shenyang Pharmaceutical University, Shandong University, Tianjin Institute of Pharmacology, National Drug Screening Center of Institute of Pharmacology of China Academy of Medical Sciences, Tsinghua University Research Center for Modernization of Traditional Chinese Medicine, Institute of Medicinal Plants of China Academy of Medical Sciences, Yantai Coastal Research Institute of Chinese Academy of Sciences, Institute of Marine Biology of Far East Branch of Russian Academy of Sciences, Beijing Gu Wei Biomedical Co., Ltd. (National Engineering Research Center for New Vaccines), American Hamner Institute, Singapore Kangsheng Hospital, Singapore Jurong International Co., Ltd., Nippon Science Co., Ltd., Softbank China Venture Capital Co., Ltd. and American trout Capital Group 19 signed an admission framework agreement with Shandong International Biotechnology Park to carry out admission cooperation and actively carry out R&D innovation, pilot incubation and supporting services.

At present, the first batch of 25 projects have signed an agreement with the park and officially settled in the R&D area of the Science Park. On this basis, the park will continue to deepen cooperation with all parties, promote mutual benefit and win-win, and realize the sustainable development of the park.

In the near future, Shandong International Biotechnology Park will become a biotechnology innovation park with domestic first-class, international advanced, concentrated advantages and outstanding characteristics, and an entrepreneurial paradise for outstanding biotechnology talents at home and abroad.